Erratum: Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy inthe PLANET study: A randomized clinical trial(JAMA Ophthalmol (2018) DOI: 10.1001/jamaophthalmol.2018.1804);Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study a randomized clinical trial

JAMA Ophthalmology

Volumn 136, Issue 7, 2018, Pages 786-793

  Lee, Won Ki ^a   Iida, Tomohiro ^b   Ogura, Yuichiro ^c   Chen, Shih Jen ^d   Wong, Tien Yin ^e,f   Mitchell, Paul ^g   Cheung, Gemmy Chui Ming ^e,f   Zhang, Zhongqi ^h   Leal, Sergio ^h   Ishibashi, Tatsuro ⁱ  

^a The Catholic University of Korea   (South Korea)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g UNIVERSITY OF SYDNEY   (Australia)

^h BAYER PHARMA AG   (Germany)

ⁱ KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; FUSION PROTEIN; PHOTOSENSITIZING AGENT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; AUSTRALIA; BEST CORRECTED VISUAL ACUITY; CENTRAL SUBFIELD THICKNESS; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; FEMALE; GERMANY; HONG KONG; HUMAN; HUNGARY; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; SINGAPORE; SOUTH KOREA; TAIWAN; VISUAL ACUITY; VISUAL IMPAIRMENT; VISUAL SYSTEM PARAMETERS; VITREOUS HEMORRHAGE; CHOROID; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; EYE FUNDUS; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; POLYP; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VASCULARIZATION;

AGED; ANGIOGENESIS INHIBITORS; CHOROID; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; FEMALE; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLYPS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85050893479     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2018.1804     Document Type: Erratum

References (25)

1. Wong RL, Lai TY. Polypoidal choroidal vasculopathy: An update on therapeutic approaches. J Ophthalmic Vis Res. 2013;8(4): 359-371.
2. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10(1):1-8.
3. Byeon SH, Lee SC, Oh HS, Kim SS, Koh HJ, Kwon OW. Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn J Ophthalmol. 2008;52(1):57-62.
4. Ladas ID, Rouvas AA, Moschos MM, Synodinos EE, Karagiannis DA, Koutsandrea CN. Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek population. Eye (Lond). 2004;18(5):455-459.
5. Lafaut BA, Leys AM, Snyers B, Rasquin F, De Laey JJ. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol. 2000;238(9): 752-759.
6. Scassellati-Sforzolini B, Mariotti C, Bryan R, Yannuzzi LA, Giuliani M, Giovannini A. Polypoidal choroidal vasculopathy in Italy. Retina. 2001;21(2): 121-125.
7. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.e5.
8. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
9. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
10. Bayer. Eylea [prescribing information]. http://www.eylea.co.uk/static/documents/Eylea -Vials-PI-UK-007-2-Clean.pdf. Accessed February 12, 2018.
11. Genentech. Lucentis [prescribing information]. https://www.gene.com/download/pdf/lucentis -prescribing.pdf. Accessed February 12, 2018.
12. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738.
13. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
14. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7): 1399-1411.
15. Wong CW, Cheung CM, Mathur R, et al. Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: Retrospective study and systematic review. Retina. 2015;35(8):1577-1593.
16. Koh A, Lee WK, Chen LJ, et al. EVEREST study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453-1464.
17. Lee WK, Kim KS, KimW, Lee SB, Jeon S. Responses to photodynamic therapy in patients with polypoidal choroidal vasculopathy consisting of polyps resembling grape clusters. Am J Ophthalmol. 2012;154(2):355-365.e1.
18. HosokawaM, Shiraga F, Yamashita A, et al. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015;99(8):1087-1091.
19. Cho HJ, Kim KM, Kim HS, et al. Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2016;165:1-6.
20. Lee JE, Shin JP, Kim HW, et al; VAULT study group. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study. Graefes Arch Clin Exp Ophthalmol. 2017;255(3):493-502.
21. Ijiri S, Sugiyama K. Short-term efficacy of intravitreal aflibercept for patients with treatment-naive polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(3): 351-357.
22. Inoue M, Arakawa A, Yamane S, Kadonosono K. Short-term efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy. Retina. 2014;34(11):2178-2184.
23. Oishi A, Tsujikawa A, Yamashiro K, et al. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol. 2015; 159(5):853-60.e1.
24. MatsumiyaW, Honda S, Otsuka K, et al. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255(3):541-548.
25. Koh A, Lai TYY, Takahashi K, et al; EVEREST II study group. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: A randomized clinical trial. JAMA Ophthalmol. 2017; 135(11):1206-1213.